v3.26.1
Revenue - Implied Share of Net Sales (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Viatris | YUPELRI Monotherapy | Theravance Biopharma, Inc.    
Revenues:    
Revenues $ 21,851 $ 20,420